Please assess the completion status of the following clinical trial:

Trial Title: High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1~* Minimum 6-month history of hypertension and primary glomerular disease~* Hypertensive nephrosclerosis~* Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1~Exclusion Criteria:~* Persistent hypertension~* New anti-hypertensive medications started within 6 weeks of Visit 1~* Significant cardiac disease or Liver disease~* Females of childbearing potential without reliable contraception~* Pregnant women and women who are breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).